SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

NCT07022002 ↗

Phase 2 Recruiting 340 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.

NaSingle-groupOpen-labelTreatment

Summary

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.

Timeline

Start: 2025-07-30
Primary completion: 2026-12-31
Completion: 2027-12-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SSGJ-705	Unknown	—	—

Indications

No indication recorded.